Direct thrombin inhibitor therapy in the cardiovascular patient

American Journal of Health-System Pharmacy

Volumn 60, Issue 20 SUPPLIMENT 5, 2003, Pages

  Chesebro, James H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angioplasty; Anticoagulants; Argatroban; Bivalirudin; Cardiovascular diseases; Desirudin; Excretion; Heparin; Lepirudin; Prothrombin time; Thrombocytopenia; Toxicity

Indexed keywords

ANTITHROMBIN;

ANGIOPLASTY; ARTICLE; CARDIOVASCULAR DISEASE; HUMAN; PATHOPHYSIOLOGY; THROMBOSIS; TREATMENT OUTCOME; UNITED STATES;

ANGIOPLASTY; ANTITHROMBINS; CARDIOVASCULAR DISEASES; HUMANS; THROMBOSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 1542709663     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.1093/ajhp/60.suppl_5.s19     Document Type: Conference Paper

References (26)

1. Fuster V, Badimon L, Badimon JJ et al. The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med. 1992; 326:242-50.
2. Giesen PL, Rauch U, Bohrmann B et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci. 1999; 96:2311-5.
3. Toschi V, Gallo R, Lettino M et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997; 95:594-9.
4. Heras M, Chesebro JH, Webster MW et al. Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury. Arterioscler Thromb. 1992; 12:250-5.
5. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: Mechanisms and clinical therapeutic approaches. Vasc Med. 1998; 3:231-9.
6. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med. 1995; 332:1374-6.
7. Greinacher A, Völpel H, Janssens U et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999; 99:73-80.
8. Greinacher A, Janssens U, Berg G et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation. 1999; 100:587-93.
9. Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001; 103:1838-43.
10. Zoldhelyi P, Bichler J, Owen WG et al. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation. 1994; 90:2671-8.
11. Zoldhelyi P, Webster MW, Fuster V et al. Recombinant hirudin in patients with chronic, stable coronary artery disease: safety, half-life and effect on coagulation parameters. Circulation. 1993; 88:2015-22.
12. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996; 335:775-82.
13. Serruys PW, Herrman JP, Simon R et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med. 1995; 333:757-63.
14. Metz BK, White HD, Granger CB et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb trial. J Am Coll Cardiol. 1998; 31:1493-8.
15. Jang I-K, Brown DF, Giugliano RP et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol. 1999; 33:1879-85.
16. White H, Simes RJ, Alyward PE et al. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001; 358:1855-63.
17. Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003; 289:853-63.
18. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet. 2002; 359:294-302.
19. Bush L. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev. 1991; 9:247-63.
20. Parry MA, Maraganore JM, Stone SR. Kinetic mechanism for the interaction of hirulog with thrombin. Biochemistry. 1994; 33:14807-14.
21. Simoons ML. Foreword. Eur Heart J. 1995; 16:1-2. Supplement.
22. EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994; 330:956-61.
23. Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet. 1999; 353:429-38.
24. Mehta SR, Eikelboom JW, Rupprecht H-J et al. Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. Eur Heart J. 2002; 23:117-23.
25. Pinto DS, Sperling RT, Tu TM et al. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2003; 58:65-8.
26. Lewis BE, Matthai WH Jr, Cohen M et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002; 57:177-84.